ARTICLE | Company News
GenVec deal
October 24, 2005 7:00 AM UTC
GNVC signed a letter of intent to sell its myoblast cell therapy program for heart failure to an undisclosed newly formed company. GNVC, which gained the program via its 2003 merger with Diacrin Inc....